Evidence map›Paper›PMID 38236457›Full record

ArticleJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2024

Doxycycline-Loaded Calcium Phosphate Nanoparticles with a Pectin Coat Can Ameliorate Lipopolysaccharide-Induced Neuroinflammation Via Enhancing AMPK.

Suzan Awad AbdelGhany Morsy, Mona Hassan Fathelbab, Norhan S El-Sayed, Salma E El-Habashy, Rania G Aly, Sahar A Harby

Open access · hybridAbstract read
In one paragraph

Article in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Doxycycline: An essential tool for Alzheimer's disease.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Suzan Awad AbdelGhany MorsyClinical Pharmacology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt.ORCID 0000-0002-5874-194X
Mona Hassan FathelbabMedical Biochemistry Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt.ORCID 0000-0002-2752-7609
Norhan S El-SayedMedical Physiology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt.ORCID 0000-0003-4270-8544
Salma E El-HabashyDepartment of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.ORCID 0000-0003-3891-5049
Rania G AlyPathology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt.ORCID 0000-0003-1227-6357
Sahar A HarbyClinical Pharmacology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt. sahar.ahmed15@alexmed.edu.eg.ORCID 0000-0002-3782-7541
Alexandria University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroinflammation occurs in response to different injurious triggers to limit their hazardous effects. However, failure to stop this process can end in multiple neurological diseases. Doxycycline (DX) is a tetracycline, with potential antioxidant and anti-inflammatory properties. The current study tested the effects of free DX, DX-loaded calcium phosphate (DX@CaP), and pectin-coated DX@CaP (Pec/DX@CaP) nanoparticles on the lipopolysaccharide (LPS)-induced neuroinflammation in mice and to identify the role of adenosine monophosphate-activated protein kinase (AMPK) in this effect. The present study was conducted on 48 mice, divided into 6 groups, eight mice each. Group 1 (normal control), Group 2 (blank nanoparticles-treated), Group 3 (LPS (untreated)), Groups 4, 5, and 6 received LPS, then Group 4 received free DX, Group 5 received DX-loaded calcium phosphate nanoparticles (DX@CaP), and Group 6 received DX-loaded calcium phosphate nanoparticles with a pectin coat (Pec/DX@CaP). At the end of the experimentation period, behavioral tests were carried out. Then, mice were sacrificed, and brain tissue was extracted and used for histological examination, and assessment of interleukin-6 positive cells in different brain areas, in addition to biochemical measurement of SOD activity, TLR-4, AMPK and Nrf2. LPS can induce prominent neuroinflammation. Treatment with (Pec/DX@CaP) can reverse most behavioral, histopathological, and biochemical changes caused by LPS. The findings of the current study suggest that (Pec/DX@CaP) exerts a significant reverse of LPS-induced neuroinflammation by enhancing SOD activity, AMPK, and Nrf2 expression, in addition to suppression of TLR-4.

Indexed as

CalciumDoxycyclineAMP-Activated Protein KinasesAnimalsAnti-Bacterial AgentsCalcium PhosphatesLipopolysaccharidesMiceNeuroinflammatory DiseasesNF-E2-Related Factor 2PectinsPhosphatesSuperoxide DismutaseToll-Like Receptor 4AMP-Activated Protein KinasesAnti-Bacterial AgentsCalciumcalcium phosphateCalcium PhosphatesDoxycyclineLipopolysaccharidesNF-E2-Related Factor 2PectinsPhosphatesSuperoxide DismutaseToll-Like Receptor 4AMPKDoxycyclineIL-6NeuroinflammationNrf2TLR-4

Identifiers

PMID38236457
PMCPMC10796490
OpenAlexW4390976687

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.